Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: Randomized double-blind placebo-controlled trial

Neuropsychopharmacology

Volumn 37, Issue 9, 2012, Pages 2093-2100

  Sepanjnia, Khatereh ^a   Modabbernia, Amirhossein ^a   Ashrafi, Mandana ^a   Modabbernia, Mohammad Jafar ^b   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

adjunctive therapy; major depressive disorder; pioglitazone; PPAR gamma; randomized controlled trial; thiazolidinedione

Indexed keywords

CHLORDIAZEPOXIDE; CITALOPRAM; PIOGLITAZONE; PLACEBO;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DSM-IV-TR; EDEMA; FEMALE; HAMILTON SCALE; HEADACHE; HEART DISEASE; HUMAN; INCREASED APPETITE; INSOMNIA; LIVER DISEASE; MAJOR DEPRESSION; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT DISEASE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SORE THROAT; STOMACH PAIN; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; YAWNING;

ADULT; CHEMOTHERAPY, ADJUVANT; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84863987293     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.58     Document Type: Article

References (45)

1. Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M et al (2011). Double-blind randomized parallelgroup clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety 28: 297-302.
2. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B et al (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26: 607-611.
3. Apler A (2011). Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials. BMJ Open 1: e000106.
4. Berlie HD, Kalus JS, Jaber LA (2007). Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 76: 279-289.
5. Blier P, Gobbi G, Turcotte JE, De Montigny C, Boucher N, Hebert C et al (2009). Mirtazapine and paroxetine in major depression: a comparison of mono-therapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 19: 457-465.
6. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R (2010). Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167: 281-288.
7. Budni J, Lobato KR, Binfare RW, Freitas AE, Costa AP, Saavedra MD et al (2011). Involvement of PI3K, GSK-3beta and PPARgamma in the antidepressant-like effect of folic acid in the forced swimming test in mice. J Psychopharmacol (in press).
8. Chen CY, Tzeng NS, Chen YC (2010). Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry 32: 647 e7-9.
9. Eissa Ahmed AA, Al-Rasheed NM (2009). Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol 20: 635-642.
10. Fava M, Rush AJ (2006). Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 75: 139-153.
11. Garcia-Bueno B, Caso JR, Perez-Nievas BG, Lorenzo P, Leza JC (2007). Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 32: 1251-1260.
12. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC (2005). The anti-inflammatory prostaglandin 15d-PGJ2 decreases oxidative/nitrosative mediators in brain after acute stress in rats. Psychopharmacology (Berl) 180: 513-522.
13. Garcia-Bueno B, Perez-Nievas BG, Leza JC (2010). Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases? Int J Neuropsychopharmacol 13: 1411-1429.
14. Geldmacher DS, Fritsch T, Mcclendon MJ, Landreth G (2011). A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68: 45-50.
15. Heneka MT, Landreth GE (2007). PPARs in the brain. Biochim Biophys Acta 1771: 1031-1045.
16. Henkel V, Seemuller F, Obermeier M, Adli M, Bauer M, Mundt C et al (2009). Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115: 439-449.
17. Jeong EA, Jeon BT, Shin HJ, Kim N, Lee DH, Kim HJ et al (2011). Ketogenic diet-induced peroxisome proliferator-activated receptorgamma activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures. Exp Neurol 232: 195-202.
18. Jope RS (2011). Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 4: 16.
19. Joyce PR, Mulder RT, Luty SE, Sullivan PF, Mckenzie JM, Abbott RM et al (2002). Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 36: 384-391.
20. Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D et al (2009). A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol 211: 124-130.
21. Karege F, Perroud N, Burkhardt S, Fernandez R, Ballmann E, La Harpe R et al (2012). Protein levels of beta-catenin and activation state of glycogen synthase kinase-3beta in major depression. A study with postmortem prefrontal cortex. J Affect Disord 136: 185-188.
22. Kemp DE, Ismail-Beigi F, Calabrese JR (2009). Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry 166: 619.
23. Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S et al (2012). Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord 136: 1164-1173.
24. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ (2002). Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 941: 1-10.
25. Kim JM, Kim SY, Stewart R, Yoo JA, Bae KY, Jung SW et al (2011). Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord 129: 183-190.
26. Maes M, Libbrecht I, Van Hunsel F, Campens D, Meltzer HY (1999). Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19: 177-182.
27. Marcus RN, Mcquade RD, Carson WH, Hennicken D, Fava M, Simon JS et al (2008). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28: 156-165.
28. Miller BW, Willett KC, Desilets AR (2011). Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann Pharmacother 45: 1416-1424.
29. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B et al (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11: 680-684.
30. Munhoz CD, Garcia-Bueno B, Madrigal JL, Lepsch LB, Scavone C, Leza JC (2008). Stress-induced neuroinflammation: mechanisms and new pharmacological targets. Braz J Med Biol Res 41: 1037-1046.
31. Nelson JC, Mazure CM, Jatlow PI, Bowers Jr MB, Price LH (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55: 296-300.
32. Ponce-Lopez T, Liy-Salmeron G, Hong E, Meneses A (2011). Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3beta decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res 1426: 73-85.
33. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF (2010). Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Scientific-World J 10: 321-328.
34. Rosa AO, Kaster MP, Binfare RW, Morales S, Martin-Aparicio E, Navarro-Rico ML et al (2008). Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry 32: 1549-1556.
35. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT et al (2011). Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168: 689-701.
36. Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, Fard YY, Dehpour AR (2011). Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res 224: 336-343.
37. Schatzberg AF (2008). Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. CNS Spectr 13: 10-12.
38. Spiegelman BM (1998). PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514.
39. Toyomoto M, Ohta M, Okumura K, Yano H, Matsumoto K, Inoue S et al (2004). Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures. FEBS Lett 562: 211-215.
40. Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DI et al (2011). Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry 72: 677-684.
41. Trivedi MH, Greer TL, Grannemann BD, Chambliss HO, Jordan AN (2006a). Exercise as an augmentation strategy for treatment of major depression. J Psychiatr Pract 12: 205-213.
42. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006b). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
43. Van Calker D, Zobel I, Dykierek P, Deimel CM, Kech S, Lieb K et al (2009). Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord 114: 243-253.
44. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir S (2010). Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study. J Eval Clin Pract 16: 1124-1128.
45. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR (2007). The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 9: 449-459.